News

Mohammed Chowdhury, MD, a Temple University cardiologist, says the field is 2 to 5 years from routine clinical integration — but validation and insurance coverage remain the critical hurdles.

The Voluntary Sodium Reduction Goals, issued in October 2021, resulted in no significant reduction in sodium content among packaged foods.

The first-in-class NDSRI showed significant symptom improvement as early as week 1 across 4 phase 3 trials but carries boxed warnings for suicidality and abuse potential.

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged 45 years and older.

Thanai Pongdee, MD, discusses how PIONEER data reveal quality of life gains that go beyond symptom and biomarker control in indolent systemic mastocytosis.

Walter Liszewski, MD, discusses how dermatologists can personalize atopic dermatitis treatment using biologics, JAK inhibitors, and topicals.

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged ≥45 years.

Abbas Zaidi, MD, discusses his recent study providing 5 pain points and 5 suggested improvements for the pediatric hypertension treatment flow.

The latest episode of Moving the Needle in Medicine features Philip Adamson, MD, MSc, as he discusses ongoing changes in the way heart failure is treated and prevented.

Daniel Soteres, MD, discusses KONFIDENT-S data showing sebetralstat improved quality of life for HAE patients already stable on long-term prophylaxis.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia, the FDA approval of Furoscix ReadyFlow, and more.

The latest episode of Moving the Needle in Medicine features Philip Adamson, MD, MSc, as he discusses upcoming advancements in heart failure care.

The latest episode of Moving the Needle in Medicine features Philip Adamson, MD, MSc, as he walks through his long and successful career in cardiology.

Daniel Soteres, MD, discusses KONFIDENT-S data showing sebetralstat quickly resolves breakthrough HAE attacks in patients on long-term prophylaxis

Sanofi has discontinued development of OX40L-targeting amlitelimab for atopic dermatitis, following the heels of Kyowa Kirin's similar rocatinlimab discontinuation.

Telehealth stepped alcohol treatment reduced weekly drinking, but not the primary endpoint, among patients with chronic liver disease.

Jason Hawkes, MD, explains how new biologics and targeted therapies are advancing precision medicine and improving personalized care in atopic dermatitis.

The approval makes MannKind Corporation’s furosemide injection the first and only autoinjector delivering SC furosemide with IV-equivalent exposure.

David B.K. Golden, MD, of Johns Hopkins, discusses anaphylaxis counseling, the Anaphylm CRL, and why a new epinephrine guideline is still years away.

GLP-1 receptor agonists show early promise for psoriasis and HS, but 3 experts urge caution on mechanism, durability, and long-term safety.

Ron Blankstein, MD, explains the value of PCD-CT and its consistency in both data collection and analysis of plaque with prior technology.

IgA nephropathy shows a male predominance, but researchers have not identified why. Ramy Hanna, MD explores possible biological explanations.

Allergists explain what's settled about epinephrine nasal spray, what's not, and how to counsel patients before anaphylaxis guidelines catch up.

APPs discuss insurance barriers, dupilumab as the default COPD biologic, depemokimab adherence advantages, and why pulmonary rehab remains critically underused.

Pulmonologists weigh in on biologic selection, mepolizumab tachyphylaxis, COPD payer barriers, and why asthma outcomes far outpace COPD in real-world practice.

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

In this Q&A following EAC 2026, Blumenthal discusses perioperative anaphylaxis risk stratification, hidden OR triggers, and penicillin allergy de-labeling.

Jason Hawkes, MD, highlights issues related to prior authorization as well as raising awareness of chronic urticaria, HS, atopic dermatitis, and other diseases.